Immunoglobulin G4-related disease mimicking asthma

Hiroshi Sekiguchi MD1, Ryohei Horie MD1, Timothy R Aksamit MD1, Eunhee S Yi MD2, Jay H Ryu MD1

Immunoglobulin (Ig) G4-related disease (also known as ‘IgG4-related sclerosing disease’, ‘IgG4-related systemic disease’ or ‘hyper-IgG4-disease’) is a recently recognized systemic fibroinflammatory disease associated with numerous IgG4-positive plasma cells with an IgG4+/IgG+ cell ratio of 0.6 (Figure 2C and 2D). Diagnosis of IgG4-RD was made and the patient was referred to the Mayo Clinic (Minnesota, USA) for further evaluation.

Physical examination was unremarkable except for bilateral submandibular gland enlargement. Pulmonary function testing (PFT) demonstrated borderline airflow obstruction with a forced expiratory volume in 1 s (FEV1) forced vital capacity ratio of 0.6, FEV1 of 85% of predicted normal value and positive methacholine challenge. Serum protein electrophoresis showed polyclonal hypergammaglobulinemia with serum immunoglobulin (Ig) level of 25 g/L (normal range 0.6 g/L to 15 g/L) and IgG4 level of 20.2 g/L (normal range 0.08 g/L to 1.4 g/L). Other laboratory tests were normal including complete blood count with differentials, chemistries, angiotensin converting enzyme level and vasculitis/connective tissue serological panel. Bronchoscopy demonstrated inflammatory changes along the tracheobronchial tree. Mucosal biopsy of the right carina 1 revealed dense chronic inflammation in the bronchial wall. Immunostaining for IgG4 highlighted 15 to 20 IgG4-positive plasma cells per high-power field (Figure 2A and 2B). Needles aspiration of hilar and mediastinal lymphadenopathy was negative for malignancy. Outside submandibular gland pathology slides were retrieved and examined using immunostaining, which demonstrated numerous IgG4-positive plasma cells with an IgG4/IgG+ cell ratio of 0.6 (Figure 2C and 2D). Diagnosis of IgG4-RD was made and the patient was referred to the Mayo Clinic (Minnesota, USA) for further evaluation.

Learning objectives

- Learn multiorgan manifestations of immunoglobulin G4-related disease (IgG4-RD) and its responsiveness to corticosteroids.
- Recognize IgG4-RD as a possible etiology of refractory asthma-like symptoms.

Pre-test

- What is IgG4-RD?
- What laboratory tests are of value in making a diagnosis of IgG4-RD?
- What are the typical pathological findings seen in IgG4-RD?
- What is the first-line treatment for IgG4-RD?

CASE PRESENTATION

A 44-year-old male nonsmoker presented with a two-year history of sinus congestion, wheezing, dyspnea and cough. Pharmacological treatment, including antibiotics, inhaled corticosteroids and antihistamines, did not improve his symptoms. Submandibular gland enlargement was apparent one year after the onset of symptoms. Left submandibular gland biopsy performed at another hospital revealed chronic sialadenitis. Sialadenitis and other symptoms improved after several weeks of oral prednisone; however, these manifestations recurred three months after discontinuation of prednisone therapy. A computed tomography (CT) scan of the neck, chest and abdomen demonstrated enlarged submandibular glands, as well as hilar and mediastinal lymphadenopathy, a 2.5 cm spiculated infiltrate in the left upper lobe of the lung and a 2.5 cm low-attenuation mass in the left kidney (Figures 1A, 1B, 1C and 1D), with no evidence of pancreatic abnormalities. The patient was referred to the Mayo Clinic (Minnesotta, USA) for further evaluation.

Needle aspiration of hilar and mediastinal lymphadenopathy was negative for malignancy. Outside submandibular gland pathology slides were retrieved and examined using immunostaining, which demonstrated numerous IgG4-positive plasma cells with an IgG4/IgG+ cell ratio of 0.6 (Figure 2C and 2D). Diagnosis of IgG4-RD was made and the patient was referred to the Mayo Clinic (Minnesota, USA) for further evaluation.

1Division of Pulmonary and Critical Care Medicine; 2Division of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

Correspondence: Dr Hiroshi Sekiguchi, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905, USA.

Telephone 507-284-2416, fax 507-266-4372, e-mail sekiguchi.hiroshi@mayo.edu

©2013 Pulsus Group Inc. All rights reserved
IgG4-RD is a corticosteroid-responsive disorder. Although the optimal regimen of corticosteroid therapy has not been determined, most patients respond to a prednisone dose of 0.6 mg/kg per day (22). Favorable response is usually observed in two to four weeks of treatment. After the initial two to four weeks of treatment, the prednisone dose is gradually decreased over the following few months, with continued monitoring for complete resolution or possible recurrence. Maintenance therapy with lower doses of prednisone (5 mg to 10 mg daily) has been shown to reduce the relapse rate in patients with pancreatic manifestation of IgG4-RD (22).

Our case was unique in that the patient presented with clinical features mimicking asthma associated with other organ involvement. PFT demonstrated borderline airflow obstruction with positive methacholine challenge, and bronchoscopy revealed inflammatory changes in the tracheobronchial tree. Immunostaining of the endobronchial mucosal biopsy showed an increased number of IgG4-positive plasma cells. One case of IgG4-RD has previously been reported manifesting central airway stenosis due to lymphadenopathy in a patient with AIP; however, there has been no previous description of diffuse mucosal inflammation in the tracheobronchial tree as seen in our patient (16).

IgG4-RD is an under-recognized disorder and it appears likely that some patients with central airway inflammation related to IgG4-RD may have been misdiagnosed with asthma. Along this line, a recent cross-sectional study demonstrated that 19% of IgG4-RD patients had been previously diagnosed with allergic disorders, such as bronchial asthma, sinusitis or allergic rhinitis (5). The measurement of serum IgG4 level may facilitate the diagnosis of IgG4-RD if the clinical presentation seems atypical for asthma or the patient exhibits multiple organ involvement.

Although multiple organs (salivary glands, intrathoracic lymph nodes, lung and kidney) were affected, our patient did not demonstrate evidence of pancreaticobiliary disease, which is the most common presentation of IgG4-RD (5). Salivary gland involvement is the second most common manifestation and it generally causes firm, nodular swelling that is associated with pain, tenderness and decreased saliva production (4,5). Infrathoracic lymphadenopathy is also a relatively common manifestation of IgG4-RD. A previous study showed that 78% of AIP patients had infrathoracic lymphadenopathy (17). Other pulmonary manifestations involve parenchymal infiltrates, pleural effusion and pleuritis (1). The most common CT or ultrasonographic findings of renal involvement are single or multiple low-attenuation lesions followed by bilateral diffuse kidney enlargement (3,18). Tubulointerstitial nephritis is a dominant pathological feature characterized by abundant IgG4-positive plasma cell infiltration into the renal interstitium with fibrosis (3,18). Overall, radiological changes in any affected organs can mimic infectious or malignant infiltrates and its differentiation can be difficult via radiological findings alone. Serum IgG4 level can be within the normal range in 20% of patients with IgG4-RD and elevated in other diseases (6,7,19). Thus, an elevated serum IgG4 level alone is insufficient to confirm the diagnosis of IgG4-RD. No correlation has been observed between serum levels of other IgG subclasses and IgG4-RD. In addition, IgG4-RD patients are at higher risk of developing malignancy than the general population (20,21). Therefore, biopsy is often required to make a definitive diagnosis of IgG4-RD or to differentiate another organ manifestation from malignancy.

IgG4-RD is a recently recognized fibroinflammatory systemic disease that often presents as autoimmune pancreatitis (AIP) but can affect virtually any organ. There have been reports describing a broad spectrum of organ involvement including biliary system, salivary glands, periorbital tissues, kidneys, lungs, lymph nodes, meninges, aorta, breast, prostate, thyroid gland, pericardium and skin (1-5). Thus, the clinical presentation varies widely and depends on the organs affected. The pancreas is one of the most commonly affected organs, and patients with AIP often present with abdominal pain and obstructive jaundice. However, an inflammatory pulmonary infiltrate or a kidney lesion may not cause symptoms. Patients with IgG4-RD typically demonstrate high serum IgG4 levels and polyclonal hypergammaglobulinemia; however, approximately 20% of patients with biopsy-proven IgG4-RD may have normal serum IgG4 values at diagnosis (6,7). Characteristic histopathological features include abundant IgG4-positive lymphoplasmacytic infiltration, fibrosis, and obliterator phlebitis or arteritis (1,4,8). In extrapancreatic sites of IgG4-RD, all three pathological features may not be present (5,9). Immunohistochemical staining for IgG4 and IgG is often used to quantify the amount of IgG4-positive cells in the affected tissues. Several different cut-offs have been proposed for diagnosis of IgG4-RD, which include the absolute number of IgG4-positive cells per high-power field >10 to 50, and the ratio of IgG4-positive cells to normal serum IgG4 values at diagnosis (6,7). Characteristic histopathological features include abundant IgG4-positive lymphoplasmacytic infiltration, fibrosis, and obliterator phlebitis or arteritis (1,4,8). In extrapancreatic sites of IgG4-RD, all three pathological features may not be present (5,9). Immunohistochemical staining for IgG4 and IgG is often used to quantify the amount of IgG4-positive cells in the affected tissues. Several different cut-offs have been proposed for diagnosis of IgG4-RD, which include the absolute number of IgG4-positive cells per high-power field >10 to 50, and the ratio of IgG4-positive cells to

DISCUSSION

IgG4-RD is a corticosteroid-responsive disorder. Although the optimal regimen of corticosteroid therapy has not been determined, most patients respond to a prednisone dose of 0.6 mg/kg per day (22). Favorable response is usually observed in two to four weeks of treatment. After the initial two to four weeks of treatment, the prednisone dose is gradually decreased over the following few months, with continued monitoring for complete resolution or possible recurrence. Maintenance therapy with lower doses of prednisone (5 mg to 10 mg daily) has been shown to reduce the relapse rate in patients with pancreatic manifestation of IgG4-RD (22).

Can Respir J Vol 20 No 2 March/April 2013
Although many patients demonstrate an initial favourable response to corticosteroids, a substantial number of patients experience a relapse after or during the corticosteroid tapering process. A previous study involving AIP patients demonstrated relapse rates of 32% within six months of discontinuing treatment, 56% within one year and 92% within three years (22). There have been a limited number of reports regarding treatment with other immunosuppressive agents in patients with recurrent or refractory IgG4-RD. Azathioprine, mycophenolate mofetil and rituximab have been used; however, the data regarding their efficacy are limited to small retrospective case series and case reports (23-25).

CONCLUSIONS
IgG4-RD is a recently recognized systemic fibroinflammatory disease characterized by a high serum IgG4 level, abundant IgG4-positive lymphoplasmacytic infiltration in various organs and steroid responsiveness. Clinical presentations can mimic various diseases such as infectious, malignant and other inflammatory disorders. Increased awareness of IgG4-RD is important to avoid diagnostic delay and to facilitate the appropriate treatment to prevent irreversible organ damage.

REFERENCEs
Submit your manuscripts at
http://www.hindawi.com